QIAGEN: The Picks and Shovels of the Genomics Gold Rush

I. Introduction & Episode Roadmap

On the morning of October 21, 2026, two press offices in the Netherlands, one in Venlo and one in Amsterdam, released the same document at the same moment. It announced that a holding company called Crown NL Bidco, controlled by the Swedish private equity firm EQT and backed by Abu Dhabi's sovereign wealth fund and Canada's largest pension plan, would offer €46.50 in cash for every share of QIAGEN.¹

The price was about 40% above where the stock had closed on July 8, the last quiet day before the market heard that buyout firms were circling, and it valued the whole business at roughly €10.8 billion, or about $12.1 billion including its debt.¹ Both of QIAGEN's boards backed it unanimously. Its new chief executive, in the job for less than two months, said that under private ownership the company could "move faster."¹

On the same day, almost as a footnote, QIAGEN told investors that its third quarter had produced $548 million of sales, essentially flat against the year before once currency moves were stripped out, and that it was withdrawing its full-year forecast while the deal was pending.²

Those two announcements, side by side, are the whole puzzle of this story. Here is a company that sits underneath a remarkable share of the world's molecular biology. When a cancer lab, a forensic lab, a tuberculosis clinic or a vaccine researcher needs to pull DNA or RNA out of blood, tissue, saliva or wastewater, there is a decent chance the little spin column, the kit or the robot doing it carries the QIAGEN name.

Nine of every ten dollars it earns come from consumables, the kits and reagents that labs buy again and again.³ It has been profitable through most of four decades, it threw off about $450 million of free cash in 2025, and its operating margin that year was roughly a quarter of sales.³ And yet the business that EQT is buying has barely grown in four years, has twice been judged worth more by an outside buyer than by the public market, and has now put itself up for sale for the second time in six years.

The founders liked to explain the company with a story about California in 1849. Peer Schatz, the Austrian-born finance chief who would later run QIAGEN as chief executive, put it to the Financial Times this way: "You know in the gold rush it was the Levi Strausses and Wells Fargoes that made the money, not the gold diggers."⁴ QIAGEN would not try to cure cancer or invent a gene therapy. It would sell the picks and shovels to everyone who did.

That idea is one of the great strategic simplifications in life sciences, and for a long time it worked spectacularly. A PhD thesis in Düsseldorf turned into a German start-up that listed on Nasdaq before it listed at home, then into a global standard for sample preparation, then into an acquisition machine that bought its way into cancer screening, tuberculosis testing, bioinformatics and syndromic diagnostics.

Then came a pandemic that made QIAGEN's products, briefly, among the most sought-after objects in medicine, and that blew up a takeover by Thermo Fisher Scientific because shareholders decided the company was worth more than the world's largest life-science tools group was willing to pay.

This story follows that arc and tests it. It asks whether the picks-and-shovels model is a durable moat or a beautiful phrase, whether QIAGEN's long string of acquisitions created value or merely created revenue, what really happened when the company bet on sequencing instruments and integrated PCR machines of its own, and why a business with such sticky customers has struggled to grow since the pandemic faded. It ends where the company stands tonight: a recommended cash offer on the table, a new chief executive who has never reported a full quarter, and shareholders who, six years ago, said no to a lower price.

The question that runs underneath everything is the one the Davidson Kempner fund asked loudly in 2020 and EQT is answering with cash in 2026. What is a company worth when it owns the first step of almost every genetic test, but not the growth that happens after it?

↑ Back to Top

II. Founding Story: From PhD Thesis to Biotech Pioneer (1984-1995)

In 1983, a young chemist named Metin Colpan finished his doctoral thesis in Düsseldorf.⁴ The problem he had been working on sounds mundane and turned out to be foundational. Every experiment in molecular biology starts with the same chore: get the nucleic acid out. DNA and RNA live inside cells, tangled up with proteins, fats, sugars and salts.

Before a scientist can copy a gene, cut it, sequence it or test it for a mutation, they need a clean sample of it. In the early 1980s that usually meant hours of hazardous work with phenol and chloroform, ultracentrifuges and a lot of patience, and the results varied from one pair of hands to the next.

Colpan's work led to a resin-based method for purifying DNA that would become, in the words of one company history, "a standard throughout the world."⁴ A simple way to picture it is a very selective sieve. A sample is poured through a column packed with a specially treated material; under one set of salt conditions the DNA sticks and everything else washes through, and under another it lets go, clean and ready to use. What had been an art became a recipe.

In 1984, three doctoral students, Colpan, Karsten Henco and Jürgen Schumacher, founded a company in Düsseldorf with the backing of their supervisor, the 43-year-old biophysicist Detlev Riesner.⁵ They called it Diagen, a blend of "diagnostics" and "genetics," and it was one of the first biotech spin-offs from a German university.⁵ The money came from an unlikely place. Colpan met the California venture investor Moshe Alafi for a single hour at Frankfurt airport and left with a letter of commitment; in all, he raised about $3 million, and the company later claimed to be the first venture-capital-backed company in Germany.⁴

The breakthrough product arrived in the summer of 1986, when Colpan designed a two-part, single-use plastic system for extracting nucleic acids, the ancestor of the spin columns that still fill laboratory drawers today.⁵ It solved the purification problem in a form a lab technician could buy in a box. That detail matters more than it seems. A method published in a journal can be copied by anyone; a disposable kit, made the same way every time, used once and thrown away, is something a lab orders again next month.

A hostile home market

The timing, though, was awful. West Germany in the mid-1980s was not a friendly place for genetic engineering. Public suspicion of the technology was intense, and the forced shutdown of another company's insulin production facility left the country's biotech sector shaken for the better part of a decade.⁴ German customers who should have been Diagen's natural buyers kept their distance.⁴ The young company made matters worse by chasing too many applications at once, spreading a tiny team across products that each needed their own development and sales effort.⁴

Facing financial failure, the company did what many German technology companies of that era could not bring themselves to do: it turned its back on its home market and went to America.⁴ The United States had a booming academic research base, the National Institutes of Health funding thousands of labs, and a biotech industry that treated genetic engineering as an opportunity rather than a threat. It also had a culture of buying tools rather than making them in-house, which was exactly the habit Diagen needed.

The pivot came with a clarified strategy. Rather than compete in the end products, drug development and gene therapy, which required years of costly research with no guarantee of success, the company would stay focused on what it called "the picks and shovels" of the new gold rush.⁴ It was renamed QIAGEN, and when it took that name it still had only about 20 employees.⁵ By the end of 1991 sales were still under $10 million, but the company had turned profitable.⁴

Two years later, in 1993, QIAGEN hired a new chief financial officer, the Austrian-born and American-educated Peer Schatz.⁴ Schatz would spend 27 years at the company and, as chief executive, become the architect of its expansion.⁶ He was a dealmaker by temperament, comfortable with capital markets in a way few German scientists of the time were, and he gave the company its gold-rush vocabulary. It is worth noticing what that vocabulary did. It reframed the strategy as a strength.

The early record supports a narrower version of that claim than the slogan suggests. The picks-and-shovels strategy did protect QIAGEN from binary scientific risk, and it gave the company a product that customers reordered. But it also tied QIAGEN's fortunes to its customers' budgets. When research money flowed, kits flew off the shelves.

When academic funding tightened or a lab cut back, the shovel-seller felt it just as surely as the miners did, only a little later. That tension, invisible in the 1990s boom, would define the company three decades on. In the meantime, the boom was about to arrive, and QIAGEN was about to ride it onto an American stock exchange before it ever listed in Frankfurt.

↑ Back to Top

III. IPO & Expansion: Becoming the Global Standard (1996-2006)

By 1996 the obscure Düsseldorf start-up had about 450 employees and roughly $54 million in annual sales, and it did something almost unheard of for a German company: it listed its shares on Nasdaq before listing at home.⁵⁴ A year later it added a listing on Frankfurt's new technology market, the Neuer Markt.⁴ The order of those two events tells the story of the decade. QIAGEN went to New York first because that was where its customers were, where its investors understood the tools business, and where a company could raise money to grow without apologizing for being in genetics.

The same year brought the first step into automation. QIAGEN launched the BioRobot 9600, its first automated system for purifying nucleic acids.⁵ For a lab processing a few samples a day, a spin column was enough. For a lab processing hundreds, the bottleneck was human hands, and a robot that ran QIAGEN's chemistry overnight solved it. The company was clear-eyed about where the money was. The machines remained a sideline to the consumables business, a way to sell more kits rather than a business in their own right.⁴ Kits sold for anywhere from $50 to $2,500 each and returned margins of up to 70%.⁴

That is the economic engine of this whole story, and it is worth slowing down to understand it. Think of a printer and its ink, or a razor and its blades. QIAGEN sold the instrument, sometimes at thin margins, and then sold the reagents that ran on it for years.

Every validated laboratory protocol that specified a QIAGEN kit made the next order more likely, because changing the kit meant re-validating the whole workflow, and in a regulated clinical lab re-validation is slow, expensive and risky. The customer was not buying a box of chemicals so much as buying the right not to think about step one.

The Hilden years

The money from the listings went into scale. In 1997 the company built its headquarters in Hilden, a town just outside Düsseldorf, after years of operating out of space sublet from the chemicals group Henkel.⁵ The legal parent company was eventually domiciled in Venlo, just across the Dutch border, while Hilden remained the operating heart, a structure that persists today and is why the 2026 offer is being made to a Dutch company under German takeover rules.¹

By the end of the 1990s, QIAGEN was said to be seven times larger than all of its primary competitors in its niche combined, with more than 250 products and more than 150,000 customers worldwide.⁴ Sales reached about $144 million in 1999.⁴ And then the market did what markets do at the end of a decade like that one. At the height of the genomics excitement around the Human Genome Project, QIAGEN's shares traded at roughly 295 times earnings, valuing the company at about $6 billion.⁴

That number deserves a pause, because it is a useful anchor for everything that follows. At the turn of the millennium, investors valued a company with under $150 million of sales at about $6 billion. A quarter-century later, EQT is offering roughly twice that for a company with fourteen times the revenue. The picks-and-shovels story has always been easy to fall in love with, and the price of that love has swung enormously.

Schatz used the expensive currency to buy. QIAGEN acquired Rosys Instruments in 1998 and, in June 2000, Operon Technologies, a maker of synthetic DNA, for about $110 million in stock.⁴ The company had forecast that sales could reach $1 billion by 2005.⁴ That target was missed: QIAGEN did not get there by 2005, and as the next chapters show, it needed a very large acquisition to approach it. The genomics bubble deflated, the stock fell back to earth, and QIAGEN spent the early 2000s doing the less glamorous work of broadening its kit catalog and its automation range.

What the expansion era established, and what still holds, is that QIAGEN became the default first step of molecular biology. Its 2025 annual report shows consumables and related revenue at $1.88 billion, about 90% of sales, with instruments contributing the other 10%.³ That mix has barely changed in a generation, and it is both the company's greatest strength and the reason it eventually had to look further down the workflow for growth.

Sample preparation is essential, but it is also the cheapest part of a test. If a hospital spends money detecting a virus, most of that money goes to the test that names the virus, not the kit that cleaned the sample. By the mid-2000s, Schatz had concluded that QIAGEN needed to own the answer as well as the first step. In 2007 he went shopping for the answer.

↑ Back to Top

IV. The Digene Acquisition: Entry into Molecular Diagnostics (2007)

On Sunday, June 3, 2007, QIAGEN and Digene, a diagnostics company based in Gaithersburg, Maryland, announced that they would combine.⁷ The terms were rich. Digene shareholders could choose $61.25 in cash or 3.545 QIAGEN shares for each share they held, with the total split roughly 55% cash and 45% stock, a 37% premium to the previous Friday's close.⁷ The total equity consideration came to about $1.6 billion.⁷ For a company that had been selling DNA purification kits for two decades, this was a bet-the-strategy deal.

Schatz did not undersell it. "This transaction creates significant value for our shareholders and instantaneous market and technology leadership in what is one of the most exciting areas of life sciences and healthcare," he said.⁷

He also framed the deal in the language investors cared about. QIAGEN told shareholders that Digene would dilute its adjusted earnings by three to four cents a share in the last quarter of 2007 and then add two to four cents in 2008, and that the deal was expected to close around August or September.⁷ In other words, the company was asking investors to pay a 37% premium today for a business that would pay for itself almost immediately. That kind of promise is easy to make about a franchise that is growing, and it rests on the assumption that the franchise keeps growing.

To understand why QIAGEN wanted Digene, it helps to understand what Digene sold. Cervical cancer is caused overwhelmingly by persistent infection with high-risk strains of the human papillomavirus. For decades, screening relied on the Pap smear, in which a pathologist looks at cells under a microscope for signs of abnormality. Digene's hybrid capture test looked instead for the virus's DNA itself. If the virus was not there, the woman's risk was very low; if it was, she needed closer follow-up. Digene's chief executive told investors the business was running at more than $200 million a year in revenue.⁷

For QIAGEN the logic was the gold-rush logic taken one step further. Instead of selling the shovel to the miner, it would own a mine of its own, but a particular kind of mine: a high-volume, recurring, guideline-driven test performed on millions of women every year. The combined company expected more than $350 million of molecular diagnostics revenue and more than $800 million of total revenue in 2008.⁷ Overnight, diagnostics went from a sideline to more than 40% of the business.

What the crown jewel became

Here the story needs its first serious fact-check, because the way the Digene deal is usually told, as the moment QIAGEN became a diagnostics leader, is true only for a while.

A screening test's moat depends on two things: regulatory exclusivity and the absence of a better test. Digene had the first, for a time. It did not keep the second. Over the following decade, larger diagnostics companies brought their own HPV tests to market, built on fully automated PCR platforms that could run HPV alongside other tests on the same machines hospitals already owned. Guidelines in many countries shifted toward primary HPV screening, which should have been a tailwind, but the competition to supply that screening was fought on automation and menu breadth, where Digene's older technology was at a disadvantage.

The clearest evidence of what happened is what QIAGEN itself stopped talking about. When it set out its strategy to 2028 at a Capital Markets Day in New York in June 2024, it named five growth pillars: sample technologies, the QuantiFERON tuberculosis test, the QIAstat-Dx syndromic testing system, the QIAcuity digital PCR platform and the QIAGEN Digital Insights software business.⁸ HPV testing, the reason for the largest acquisition in QIAGEN's history to that point, was not among them.

That does not make the Digene deal a failure. It brought QIAGEN a sales force that called on hospital and reference laboratories, a regulatory team that knew how to get tests through the FDA, and the credibility to keep buying in diagnostics. Those capabilities carried directly into the next decade.

But it does narrow the claim. Buying a market-leading test bought a market-leading position for a number of years, not forever. In diagnostics, a cleared test is a franchise only for as long as nobody builds a better or more convenient one, and the companies with the broadest automated platforms tend to win the long game.

That lesson, that QIAGEN's natural advantage lies at the bottom of the workflow rather than in owning the instrument at the top, would come back again and again: in sequencing, in integrated PCR and arguably in the Thermo Fisher saga. In 2007, though, it was not yet visible. What was visible was a company with a new diagnostics franchise, a much bigger revenue line and a chief executive who had discovered that acquisitions could change the shape of a company in a single weekend. He would use that discovery many more times.

↑ Back to Top

V. The Acquisition Machine: Building Sample-to-Insight (2009-2019)

In April 2011, QIAGEN agreed to buy an Australian company called Cellestis for about A$341 million in cash.⁹ Cellestis was not famous. Its main product, QuantiFERON, did something unglamorous and enormously useful: it told doctors whether a person carried a dormant tuberculosis infection.

Latent TB causes no symptoms and is not contagious but can wake up years later, especially in people whose immune systems weaken. The traditional way to look for it is the tuberculin skin test, invented more than a century ago. A nurse injects a small amount of protein under the skin of the forearm, and the patient must come back two or three days later so someone can measure the bump with a ruler.

It is cheap, but it requires two visits, it is subjective, and it can show false positives in people who received the BCG vaccine, which is most of the world outside the United States. QuantiFERON replaced all of that with a single blood draw: the patient's immune cells are exposed in a tube to proteins specific to the TB bacterium, and the lab measures whether those cells react.

Of all the deals of the Schatz era, this one has aged the best. QuantiFERON became QIAGEN's single largest franchise, with sales of about $503 million in 2025, up about 10% at constant currency that year.¹⁰¹¹ Management estimated in 2024 that about 60% of the global latent TB testing market still relied on the skin test, which meant the conversion opportunity remained large more than a decade after the purchase.⁸ Paying a few hundred million dollars for a product that grew into a half-billion-dollar line is the kind of return that justifies an acquisition strategy.

Building the stack

Cellestis was one move in a campaign. The idea Schatz pursued through the 2010s had a slogan of its own, "Sample to Insight": QIAGEN would not just clean the sample, it would run the test and interpret the result. Each acquisition filled a gap in that chain.

The interpretation end of the chain came first in 2013, when QIAGEN paid $105 million in cash for Ingenuity Systems of Redwood City, California, whose knowledge base and software helped researchers and clinicians make sense of complex genetic data.¹² Software is where genomics gets interesting for a tools company. A sequencer produces enormous files of letters; the hard part is knowing which of the millions of differences between one person's genome and the reference actually matter. Ingenuity's curated databases, built by people reading the scientific literature, answered that question, and they became the core of what is now QIAGEN Digital Insights.

Ingenuity's tools were already used by tens of thousands of researchers and clinicians when QIAGEN bought it.¹² The bet was that as sequencing got cheaper, the bottleneck in genomics would move from generating data to understanding it, and that whoever owned the understanding would capture value that the machines could not. More than a decade later, that bet has produced a real business but not a large one: QIAGEN targeted about $125 million of sales from QIAGEN Digital Insights in 2026, about 6% of the group.¹¹

The testing end got a new platform in 2018. QIAGEN agreed to buy STAT-Dx, a Barcelona start-up, for $147 million in cash plus up to $44 million in milestone payments.¹³ Its system, renamed QIAstat-Dx, ran what diagnosticians call syndromic panels. Picture a child arriving at an emergency room with fever and a cough.

It could be any of a dozen viruses or bacteria. Instead of ordering tests one at a time, a syndromic panel checks for all the usual suspects in a single cartridge in about an hour. By the end of 2025, more than 5,200 QIAstat-Dx instruments had been placed and its sales grew 24% at constant currency that year.¹¹

There is an accounting consequence to building a company this way, and it still shapes how QIAGEN's numbers read. Every acquisition brings intangible assets—technology, customer relationships and brands—that must be amortized over time, and every acquisition that disappoints brings an impairment. Neither costs cash in the year it is booked.

In 2025 alone, depreciation and amortization came to about $203 million and impairments to about $22 million, alongside about $50 million of share-based pay.³ That is why QIAGEN's reported profits have consistently understated its cash generation, and why investors in the company learned to look past the income statement to the cash flow statement.

Alongside these, the company kept buying smaller technology and content businesses throughout the decade in cancer biomarkers, bioinformatics and specialty reagents. The overall shape is a serial acquirer, with each deal small relative to the company and the occasional big one setting direction.

The sequencing gamble

The Sample-to-Insight strategy had one move that went badly wrong, and it was the most ambitious one. Next-generation sequencing was the defining technology of the decade, dominated by Illumina. QIAGEN decided it would not merely supply sample preparation for other companies' sequencers. It would build and sell its own clinical sequencing system, called GeneReader, and offer customers a complete workflow from tube to report.

It is easy, in hindsight, to see the problem. Sequencing instruments live or die on scale: the cost per genome, the accuracy, the size of the installed base and the ecosystem of researchers building on it. Illumina had all of that. GeneReader had a vision. By 2018, analysts at Cowen estimated that it generated no more than $10 million to $15 million of revenue, which they called "minimal adoption."¹⁴

The bill arrived on October 7, 2019. In a single announcement QIAGEN said that Schatz was stepping down as chief executive after 27 years, that Thierry Bernard, the head of its molecular diagnostics business, would serve as interim CEO alongside finance chief Roland Sackers, and that it was suspending development of its own sequencing instruments.⁶¹⁴

It also signed a 15-year partnership with Illumina to develop diagnostic kits for Illumina's machines, warned that third-quarter growth would be about 3% at constant exchange rates instead of the 4% to 5% it had guided, blamed weakness in China and announced a restructuring with a pre-tax charge of $260 million to $265 million.¹⁴ The shares fell by more than 20% the next day; one analyst called it "clearly a bad day."¹⁴ The company's operating profit for 2019 swung to a small loss on the charges.¹⁵

The episode is the most important piece of disconfirming evidence in the QIAGEN record, because it tests the claim the company was built on. The picks-and-shovels firm had tried to become a gold miner, or at least a maker of the biggest machines in the mine, and it had lost. Its edge was in chemistry, workflow and the consumables that labs reorder; it did not extend automatically to the expensive instrument at the center of the workflow, where larger and more focused rivals had the scale. This was not the last time QIAGEN would learn that lesson.

What came next was a company with a stalled growth story, a departed founder-era chief executive, a share price that had just lost a fifth of its value, and, as Bernard and Sackers began a strategic review, several large companies expressing interest in buying it.¹⁶ The most serious of them was Thermo Fisher Scientific.

↑ Back to Top

VI. The Failed Thermo Fisher Acquisition: A Pivotal Moment (2020)

On March 3, 2020, Thermo Fisher Scientific, the world's largest life-science tools company, announced that it would buy QIAGEN for €39 a share in cash.¹⁷ The offer was about 23% above the previous day's close and valued QIAGEN at roughly $11.5 billion, including about $1.4 billion of net debt.¹⁷ Marc Casper, Thermo's chief executive, promised investors that the deal would be "immediately accretive" and would generate "significant cost and revenue synergies."¹⁷ Both boards endorsed it. The courtship had taken months; non-binding indications from bidders had ranged from about $36 to $44 a share, and QIAGEN had pushed for more before settling.¹⁶

For QIAGEN's management, it looked like a clean exit from a hard season. For Thermo, it looked like a bargain: a franchise in sample preparation and specialty diagnostics bought at a moment of weakness. The calendar, however, had other ideas. On the day the deal was announced, a new coronavirus was spreading out of China into Italy, Iran and South Korea. Within weeks it was everywhere, and the world discovered that the first step of every PCR test for SARS-CoV-2 was extracting viral RNA from a swab.

The day the shovels sold out

That was QIAGEN's first step. Laboratories that had never thought about sample preparation suddenly could not get enough of it. Extraction kits became a bottleneck in national testing programs, and QIAGEN found itself scaling up manufacturing at a speed it had never needed before. Demand also flowed to its QIAstat-Dx respiratory panels and to its testing reagents more broadly.

The financial effect was swift. In July, QIAGEN reported preliminary second-quarter sales up nearly 19% from a year earlier, an extraordinary number for a company that had been growing at low single digits.¹⁸ And here the takeover ran into a problem that almost never happens in mergers: the target's prospects were improving too quickly for the agreed price.

On July 13, Davidson Kempner Capital Management, a New York hedge fund holding about 3% of QIAGEN, published a letter calling the €39 offer inadequate.¹⁸ Its argument was simple. The pandemic had made the value of QIAGEN's testing business "significantly clearer," and absent the bid, QIAGEN shares would likely have risen alongside European diagnostics peers.¹⁸ The letter also put a number on the optimism: Davidson Kempner predicted that QIAGEN's earnings would climb 67% for the full year 2020.¹⁸

It is worth holding that forecast up against a less exciting statistic cited in the same coverage. Analysts at Cowen calculated that QIAGEN's organic growth over the previous decade had averaged about 3.4% a year.¹⁸ Both numbers were true at once. The question the shareholders were really voting on was which of them described the company that would exist after the virus.

Three days later, Thermo Fisher raised its offer by about 10% to €43 a share and lowered the minimum acceptance level from 75% of QIAGEN's shares to two-thirds.¹⁹

Shareholders say no

Davidson Kempner was not satisfied. It increased its stake to about 8%, declined to tender, and argued that QIAGEN's standalone value was as high as €52 a share.¹⁶ Other holders, many of them index and long-only funds with no public voice, quietly agreed.

When the acceptance period ended on August 10, 2020, about 47% of QIAGEN's shares had been tendered.²⁰ The threshold was two-thirds. The offer lapsed, Thermo Fisher terminated the agreement, and QIAGEN paid Thermo $95 million to reimburse its expenses.²⁰ On the same day, QIAGEN said it would carry on alone and complete the purchase of the 80.1% of NeuMoDx Molecular, a Michigan maker of integrated PCR systems, that it did not already own, for about $234 million.²¹

The usual telling of this episode is that shareholders were proven right: the pandemic made QIAGEN much more valuable, and they kept that value for themselves. The first part of that is true. Revenue jumped from about $1.5 billion in 2019 to $1.9 billion in 2020 and $2.3 billion in 2021, and operating margin climbed from a loss to about 28% at the 2021 peak.¹⁵

The second part needs more care, and the 2026 offer is what makes the test possible. Thermo's €43 was a cash price available in August 2020. EQT's €46.50 arrived more than six years later. In between, QIAGEN paid a first dividend and returned money through a series of synthetic share repurchases that combine a cash payment with a reverse share split, the latest of which, in January 2026, consolidated every 20 shares into 19.²²³

Those consolidations mean an EQT share is not the same slice of the company as a 2020 share; the January 2026 split alone accounts for about five of the eight percentage points between the two headline prices. Adding back the cash returned along the way, a holder who refused Thermo in 2020 and accepts EQT in 2027 will probably have done somewhat better than €43, but over six or seven years, not by much, and far less than the €52 that Davidson Kempner said the company was worth on its own.

So the history narrows the shareholders' verdict rather than vindicating it. They were right that €39 was too low for a company in the middle of a testing boom. They were not right, or at least not yet, that the boom revealed a permanently more valuable business. The extra value of 2020 and 2021 was real, but most of it was temporary, and the business that came out the other side looked, in its growth rate, a lot like the one that went in.

The episode also set the frame for the next six years. Having told shareholders it was worth more than Thermo would pay, QIAGEN's management now had to prove it as an independent company. It chose to do that by converting the pandemic's windfall into new platforms, and the first of those, NeuMoDx, had just been bought on the day the deal died.

↑ Back to Top

VII. COVID-19 Era & Strategic Transformation (2020-2022)

Through 2020 and 2021, QIAGEN's factories in Germany and its supply chain worked at a pace nobody had planned for. The company developed new tests quickly, pushed more output through its existing lines and, like every diagnostics firm, found itself selling into national testing programs that ordered in volumes and on timelines that bore no relation to normal laboratory purchasing.

The numbers show the scale. In 2021 QIAGEN's sales grew 20% to $2.25 billion, and products in its COVID-related groups contributed $704 million, about 31% of the total.²³ Operating profit for the year reached about $630 million, and net profit about $513 million, the highest in the company's history before or since.¹⁵

The balance sheet tells a quieter version of the same story, and it foreshadows what came next. To make sure it could meet demand, QIAGEN built inventory. Measured against the cost of what it sold, inventory swelled from about 120 days' worth in 2019 to roughly 200 days' worth by 2023, even as sales were falling.¹⁵

Then, in 2024, it dropped back to about 100 days, largely because the company wrote off stock it no longer expected to sell.³ Free cash flow peaked at about $566 million in 2022, as customers paid for pandemic-era orders, before falling to about $297 million the next year.¹⁵ A company that had been told by its shareholders that the pandemic proved its worth was, inside its warehouses, carrying the hangover of that pandemic for years.

Bernard, by then confirmed as chief executive, was determined to avoid the fate of companies that rode the testing wave and then crashed. His phrase was that QIAGEN was COVID-relevant but not COVID-dependent, and in its 2021 results the company said its non-COVID product sales had grown 22% at constant currency, ahead of its own target, while "again showing QIAGEN is not COVID dependent."²³

That claim deserves a careful test, because it was the hinge of the post-Thermo strategy. Part of the non-COVID growth in 2021 was simple recovery: in 2020 many hospitals and research labs had shut down routine work, so 2021 was flattered by an easy comparison. Part of it was real. QuantiFERON demand rebounded as screening programs resumed, and the pandemic had drawn new customers and new instruments into QIAGEN's orbit.

What happened next settles the question. After 2021, revenue fell for two straight years, by about 5% in 2022 and 8% in 2023, then went sideways in 2024 before growing about 6% in 2025.¹⁵³ Over the three years from 2022 to 2025, revenue shrank by a little under 1% a year in the company's reporting currency.³

Profits fell even harder. So the claim survives only in its narrowest form: the business that remained after COVID was not smaller than the one before it, and some franchises grew strongly. But the hoped-for step-change, a QIAGEN growing structurally faster because of what the pandemic had built, did not show up in the consolidated numbers.

The NeuMoDx lesson, again

The clearest test of how QIAGEN deployed its pandemic windfall is NeuMoDx, the integrated PCR business it bought after the Thermo deal collapsed.²¹ The logic was that hospitals wanted fully integrated PCR machines, sample in, answer out, with no technician in between, and the pandemic had shown how valuable such machines could be.

The logic was not wrong in general. It was wrong for QIAGEN. Integrated PCR systems are exactly the kind of large, central, high-capital instrument where scale players with broad test menus dominate. After the testing surge faded, hospitals did not need another platform. On June 6, 2024, QIAGEN announced that it would discontinue the NeuMoDx systems, citing market trends after the pandemic and changing customer needs, and Bernard said plainly that the company did "not see a realistic path to developing this system in a value-creating way."²⁴

It expected a pre-tax charge of about $400 million, of which about $300 million would be non-cash write-downs of inventory, equipment and acquired intellectual property.²⁴ In the second quarter of 2024 alone, the restructuring program cost about $350 million, and QIAGEN's operating profit for that quarter was a loss of about $228 million.²⁵¹⁵

Put the two episodes side by side. In 2019, QIAGEN gave up on its own sequencing instrument after years of investment. In 2024, it gave up on an integrated PCR instrument it had bought with pandemic cash. Two different technologies, five years apart, under two different chief executives, ended the same way. The history does not reject QIAGEN's ability to build instrument businesses, as the next platform shows, but it narrows it sharply: the company does well with instruments that exist to sell its consumables into new applications, and poorly with large flagship systems that must win a head-to-head platform war.

The platform that worked

That next platform is QIAcuity, a digital PCR system that QIAGEN introduced during the pandemic. Ordinary PCR tells a lab roughly how much of a target sequence is in a sample by watching how quickly the signal rises. Digital PCR splits the sample into thousands of tiny compartments, runs the reaction in each one and simply counts how many light up, which gives an absolute count rather than an estimate.

QIAGEN's version uses so-called nanoplates rather than droplets and, the company says, processes samples in about two hours rather than the five required by other systems.²⁶ Its precision made it a tool for testing wastewater for SARS-CoV-2, a way to track infection across whole cities.²⁶

QIAcuity is a fair test of whether QIAGEN learned the lesson. It is a mid-sized instrument designed to pull consumables, not a central hospital analyzer. By the end of 2025 more than 3,200 had been placed, and the company was placing over 100 a quarter even in a weak capital spending climate, with consumable sales growing at double-digit rates.¹¹

Management targeted about $100 million of QIAcuity sales for 2026.¹¹ That is meaningful but still small: roughly 5% of group revenue. The verdict on QIAcuity is that it is working, at modest scale, and the KPI that would confirm it is not placements but whether consumable pull-through per instrument keeps rising.

By the end of 2025, then, QIAGEN had a bigger installed base, a stronger balance sheet, a shrinking revenue line and a management team that had made one platform bet that was failing and one that was working. The next chapter would be about trying to prove growth without the pandemic, and about what happened when that proof did not arrive fast enough.

↑ Back to Top

VIII. Modern QIAGEN: AI, Single-Cell & The Next Frontier (2023-Present)

On June 17, 2024, QIAGEN's leadership stood on the floor of the New York Stock Exchange and laid out a plan for 2028.⁸ It had discontinued NeuMoDx eleven days earlier. The pitch was a company refocused on what it did best: five growth pillars expected to produce at least $2 billion of combined sales by 2028, about 7% compound annual sales growth at constant currency from 2024 to 2028, an adjusted operating margin of at least 31% in 2028 and at least $1 billion returned to shareholders over the period.⁸ Bernard called it a commitment from "a reinvigorated leadership team."⁸

This chapter is, in large part, the story of how that plan fared, and the answer depends on which promise is being checked.

The profitability and capital-return promises were met early. In 2025, QIAGEN's adjusted operating margin rose to 29.5%, and management said that excluding tariff and currency headwinds it had expanded by about two percentage points, enough that it expected to exceed its 2028 margin target and was reviewing that target.¹¹ Reported operating margin, which includes the charges and amortization that adjusted figures exclude, recovered to about 25% after the NeuMoDx-scarred 2024.³ Free cash flow was $453 million.¹¹

Much of that cash went back to owners. QIAGEN paid its first-ever annual dividend in 2025, about $54 million or $0.25 a share, and in January 2026 completed a $500 million synthetic share repurchase approved by about 100% of votes cast at the 2025 annual meeting.³²² By the time of its February 2026 earnings call, the company said it had returned more than $1.1 billion since 2024, already beyond the $1 billion it had promised for the full five years.¹¹

The product plan behind the 2028 targets was concrete. QIAGEN said it would more than triple the number of sales specialists supporting QIAcuity, launch more than 100 new digital PCR assays, and bring out two new sample preparation instruments: QIAsymphony Connect, an upgrade of a flagship automation system with more than 3,300 placements, and QIAsprint Connect, its entry into high-throughput automation.⁸ By early 2026 QIAsymphony Connect had launched, initial orders had been taken for QIAsprint Connect, and a small benchtop system called QIAmini was due in the autumn.¹¹

For QuantiFERON, the next generation of the test, developed with the Italian diagnostics company DiaSorin, was designed, the company said, to let laboratories process up to 75% more patients an hour; it had launched in Europe and was planned for the United States in 2026.¹¹ QIAstat-Dx submitted its first blood culture identification panels in the United States and Europe, a step into sepsis testing, where speed can decide whether a patient lives.¹¹

The AI piece of the story lives mostly in QIAGEN Digital Insights. Management committed to invest about 20% of that unit's sales in research and development and to grow its AI-enabled applications from five to at least fourteen by 2028.⁸ Genoox's Franklin platform is part of that push, and QIAGEN said it was preparing to fold Parse's large single-cell datasets into the same portfolio.¹¹

By mid-2026 the company was also promoting an AI assistant for customers called QIA Agent and a collaboration between QIAGEN Digital Insights and NVIDIA.²⁷ None of this has yet been quantified as revenue. The honest framing is that AI could make QIAGEN's curated knowledge more valuable, because large language models are only as good as the verified data they draw on, or less valuable, if general-purpose models learn to read the scientific literature well enough to replace human curation. The company's own numbers do not yet settle which.

Geography matters less than it does for many tools companies. China, a market that has hurt several Western life-science firms, accounted for only about 4% of QIAGEN's sales in 2025, and it declined at a low-teens rate in that year's fourth quarter.¹¹ The Americas, and above all American research and public-health budgets, matter far more.

Cost discipline did a lot of this work. Headcount fell from 5,765 at the end of 2024 to 5,654 a year later even as sales rose, and research and development spending dropped from about 9.3% of sales to 8.5%, partly because the NeuMoDx program was gone.³ An activist looking at those numbers would ask a fair question: is this a company sharpening its focus or harvesting a mature franchise? The honest answer is some of both. Investment shifted toward new sample preparation instruments, QIAcuity assays and acquisitions, while the broad R&D budget shrank as a share of revenue.

QIAGEN also kept buying, in smaller bites. In January 2023 it completed the purchase of Verogen, a forensic DNA sequencing company, for $150 million in cash, gaining exclusive distribution of a forensic version of Illumina's MiSeq sequencer and control of GEDmatch, the genetic genealogy database that police have used to identify suspects through distant relatives.²⁸

GEDmatch brings a distinctive risk that no kit does: its value depends on consenting users who could leave if they lose trust, and on legal norms about investigative genealogy that remain contested. In 2025 QIAGEN added Genoox, whose AI-assisted interpretation software, called Franklin, it is folding into QIAGEN Digital Insights.¹¹

Verogen was a small bet with a specific plan: QIAGEN expected the portfolio to bring in about $20 million of sales in 2023, up from about $5 million it had earned through the earlier distribution agreement.²⁸ Forensics suits QIAGEN's strengths. Crime labs work under strict chain-of-custody rules, their validated methods are hard to change, and their kits are bought again and again. It is the picks-and-shovels model applied to a courtroom.

The most important bolt-on was Parse Biosciences. On November 4, 2025, QIAGEN agreed to buy the Seattle company, founded in 2018, for about $225 million in cash upfront plus up to $55 million in milestones; Parse served more than 3,000 customers in over 40 countries, and QIAGEN expected it to contribute about $40 million of sales in 2026.²⁹ The deal closed in December.¹¹

Parse is a single-cell company, and the idea is worth explaining. Traditional genomics grinds up a tissue sample and measures the average activity of all its cells, like listening to a stadium crowd and hearing a roar. Single-cell methods measure each cell separately, so a researcher can hear individual voices: which immune cells are fighting a tumor, which are exhausted, which are rare and important.

Parse's chemistry does this by tagging the molecules inside each cell with a unique combination of barcodes while the cells stay intact, which lets labs scale to millions of cells without expensive dedicated hardware. For QIAGEN, the fit is twofold. It is another sample preparation business, a front-of-workflow consumable, and the vast datasets it generates feed the interpretation software.

The price, though, deserves a sober reading. Paying more than $225 million for about $40 million of expected sales is a multiple of over five times revenue for a business that the company expected to dilute earnings and margins at first; management said Parse and other headwinds would cost about 160 basis points of margin in 2026.¹¹ Single-cell analysis is a fast-growing field, but it is also crowded and research-budget dependent. Given the NeuMoDx record, Parse is best treated as an option on a growth market, not yet as evidence of one.

The forecast that broke

On February 5, 2026, Bernard and Sackers told analysts that 2025 sales had grown 5% at constant currency to $2.09 billion, at the high end of their range, and that the five pillars had grown 8% to $1.49 billion.¹¹ They guided to at least 5% growth in 2026, with adjusted earnings per share of at least $2.50, and Sackers walked through a detailed bridge explaining why a slow start would give way to an acceleration later in the year: the comparison against discontinued products would roll off, new instruments would launch, QuantiFERON would reaccelerate, and U.S. research funding would improve.¹¹ He said the company expected "to continue to rank among the fastest-growing companies in our sector."¹¹ For QuantiFERON specifically, the company targeted about $535 million of sales in 2026.¹¹

Eleven weeks later, on April 27, QIAGEN cut its 2026 sales growth forecast to about 1% to 2% and its earnings forecast to at least $2.43.¹⁰ First-quarter sales had fallen about 1% at constant currency against a forecast of growth.¹⁰

The main culprit was QuantiFERON, whose sales dropped 5% at constant currency, mainly because of a significant decline in immigration testing demand in the United States and the Middle East; QIAGEN now expected the franchise to be flat for the year at around 2025's $503 million.¹⁰ Bernard described this as "a rebasing of demand within this testing group during 2026 and not a change in the overall long-term opportunity for latent TB testing."¹⁰

That episode is the sharpest test of management credibility in recent years, and it cuts both ways. The bridge offered in February was specific and quantified, which is a mark of good disclosure. But it was also wrong within a single quarter, on the franchise management knew best. The immigration exposure was not new information to QIAGEN: TB screening is a standard part of U.S. immigration medical exams.

A forecast that did not stress-test the largest single product against a policy-driven drop in one customer channel says something about how much the 2026 plan leaned on optimism. To its credit, the company did not hide behind vague language once the drop came; it named the cause, quantified it and cut guidance early.

The second quarter was better than feared. Sales were flat at $535 million, the pillars grew about 5% at constant currency, sample technologies grew 9%, and QIAcuity grew at double digits, while QuantiFERON rose just 1% and QIAstat-Dx fell 7% against a strong respiratory season the year before.²⁷ Leverage, measured as net debt to adjusted earnings before interest, tax, depreciation and amortization, rose to 1.1 times from 0.7 times at the end of 2025, after the buyback and the Parse purchase.²⁷ The preliminary third quarter showed $548 million of sales and adjusted earnings of $0.65 a share.²

The detail beneath those headline figures shows where the February plan had gone off course. At the start of the year, management had set 2026 targets for each pillar: about $720 million for sample technologies, $535 million for QuantiFERON, $160 million for QIAstat-Dx, $100 million for QIAcuity and $125 million for the software unit.¹¹

By August, QuantiFERON's target had been cut to about $500 million, while the sample technologies pillar, boosted by Parse's first full year, was growing fastest at $182 million for the quarter.²⁷ Adjusted earnings per share of $0.62 and an adjusted operating margin of about 29.4% showed that the cost side was holding up even when sales were not.²⁷ Cash and short-term investments had fallen to about $0.8 billion from $1.1 billion at the end of 2025, the cost of the January buyback and the dividend.²⁷

Strip it all back, and the 2028 plan now has a split verdict. The margin and capital-return promises are on track or beaten. The growth promise of about 7% a year looks out of reach: 2025 delivered about five, and 2026 was guided to one or two before guidance was withdrawn altogether.

A new chief executive, and a buyer at the door

Meanwhile the leadership question had opened. On November 4, 2025, QIAGEN announced that Bernard, 61, who had joined the company in 2015 and run it since 2019, would step down once a successor was found.³⁰ In January 2026, Bloomberg reported that QIAGEN was weighing a sale; the shares jumped from about $47.57 to $55.62 in a week.³¹ By July, Bloomberg reported, private equity firms including EQT, Advent and KKR were considering bids.³²

On August 24, after a search of nearly ten months, the company named Jonathan Pratt chief executive from September 1.³² Pratt was an outsider to QIAGEN but not to the industry: he had most recently run Filtration Group, which he led into a $9.25 billion sale to Parker Hannifin, and earlier held senior roles at Waters, Beckman Coulter Life Sciences and Pall.³²

It is a résumé shaped by industrial operations and private equity exits. The shares fell when his appointment was announced, which analysts at William Blair read as the market lowering its odds of a takeover.³² Eight weeks later, Pratt was the chief executive quoted in the EQT press release.¹

The terms deserve to be understood precisely, because they will decide how this story ends. The offer is €46.50 in cash, with financing already committed by six banks and no financing condition.¹ It needs acceptances from at least 50% of shares plus one, regulatory and foreign-investment approvals, and an extraordinary meeting that approves what the companies call post-closing measures.¹

Those measures are how a buyer gets to 100% of a Dutch company: QIAGEN's business would be transferred to the bidder, and shareholders who did not tender would receive a cash distribution equal to the offer price minus any withholding taxes, which could leave them with less than if they had tendered.¹

The boards have committed to implement those measures if 80% of votes cast at the meeting approve them, and may still do so with less, if they judge that a substantial majority of long-term holders support the deal, a clause that explicitly contemplates discounting votes from investors who bought after the announcement "with the aim of frustrating the transaction."¹

Read that clause with 2020 in mind. In that year, a hedge fund building a blocking stake killed a deal. This time, the threshold for the offer is 50% rather than two-thirds, and the boards have given themselves room to weigh the votes of event-driven funds differently. The deal is designed so that what happened to Thermo Fisher is much harder to repeat.

William Blair's analysts estimated the price at about 15 times their forecast of 2027 earnings before interest, tax, depreciation and amortization, below the high-teens to low-twenties multiples typical of life-science transactions, while calling the offer reasonable given that "broader-based growth has remained elusive."³³ After the announcement, QIAGEN's shares traded at about €44.94 in Frankfurt, below the offer, the gap reflecting time and the risk that it does not close.³¹ If the deal has not closed within ten months because approvals are still pending, QIAGEN may pay an interim dividend of up to $0.47 a share.¹ Closing is expected in mid-2027.¹

That leaves the question every investor in QIAGEN is now actually asking: not what the company will earn in 2030, but whether €46.50 is a fair price for what it is today. Answering it requires putting the moat on trial.

↑ Back to Top

IX. Bull Case, Bear Case and the Moat

Start with how the market prices QIAGEN, because that frames everything. At the end of October 2026 its market value was about $10.4 billion and its enterprise value, including net debt, about $11.2 billion.³ That works out to about 26 times trailing earnings, almost exactly its own five-year median of about 27 times, and about 16 times trailing earnings before interest, tax, depreciation and amortization.³²⁷ Its free cash flow yield was about 4.3%.

The closest large tools peers trade richer: Thermo Fisher at about 37 times trailing earnings and Danaher at about 38 times.³⁴³⁵ Those peers are not like-for-like, since both are larger, more diversified and historically faster compounding, but the gap says the market has long assigned QIAGEN a lower-growth, single-franchise discount. Today's price is no longer a standalone valuation at all; it is the EQT offer minus a discount for time and risk.

The case for QIAGEN rests on three mechanisms, each with evidence behind it.

The first is the consumables annuity. Its customer base is so dispersed that no customer accounts for even 10% of sales or receivables.³ The installed base of sample technology instruments reached about 31,400 cumulative placements by the end of 2025.¹¹ That installed base reinforces the switching costs built into validated workflows.

The second is cash. Over the twelve years to 2025, QIAGEN generated about $5.6 billion of operating cash flow against about $2.7 billion of net profit, roughly twice its reported earnings, because large non-cash charges and amortization from acquisitions depress profit more than cash.³¹⁵ Collection discipline improved too: receivables fell from about 116 days of sales at the 2019 peak to about 70 days in 2025.³ The company has no credit rating, but gross debt of about $1.44 billion was mostly low-coupon convertible notes, against about $1.10 billion of cash and short-term investments at the end of 2025.³

The structure of that debt is unusually benign. QIAGEN issued $500 million of convertible notes due 2031 at 2.5% in 2024 and $750 million due 2032 at 2.0% in 2025, repaid $474 million of zero-coupon notes due 2027 when bondholders put them back in December 2025, and had about $485 million of unused credit lines at year-end.³ Its contingent obligations are modest, with up to about $72 million of potential acquisition milestone payments, of which about $23 million had been accrued.³ This is the profile a private equity buyer loves: steady cash that can carry debt.

Currency is a smaller risk than QIAGEN's German roots might suggest. The company reports in U.S. dollars while most of its subsidiaries work in local currencies, and it routes much of its exposure through an in-house bank and hedging contracts; net transaction losses were about $5.5 million in 2025, a rounding error against its profits.³ Its auditor flagged no going-concern doubt and issued an unmodified opinion on the 2025 accounts.³

The third is the handful of franchises that do grow. QuantiFERON still has a large pool of skin tests to convert; QIAstat-Dx grew strongly in 2025; QIAcuity is placing instruments through a capital spending drought; and the software business, QIAGEN Digital Insights, sits on curated knowledge that is hard to replicate.¹¹⁸ Under a buyer that can invest without quarterly scrutiny, the bull says, those pillars could finally outrun the mature base.

The case against is the growth record. In the company's reporting currency, revenue shrank slightly over the three years to 2025, grew about 2% a year over five and about 5% a year over ten.³ Even the five pillars, the best of the portfolio, slowed from 8% growth in 2025 to about 5% in mid-2026.¹¹²⁷ The rest of the business, roughly 30% of sales, has been flat at best.

The most important pillar suffered a policy shock that management did not anticipate. Twice, in sequencing and in integrated PCR, the company's attempts to own a central instrument platform ended in write-offs. A skeptic would say the record shows a franchise that throws off cash and buys growth, rather than one that generates it.

The governance record also bears examination. The 2026 annual meeting saw about 11% of votes cast against the remuneration report, about 17% against the amended pay policy and about 18% against two Supervisory Board candidates, unusually high dissent for routine items.³⁶

The 2024 financial statements had to be restated because the accounting for an embedded conversion feature in a convertible bond had been omitted, a technical error rather than a cash issue, but one the auditor and audit committee did not catch in the first instance.³ The auditor's key audit matter for 2025 was $143.6 million of uncertain tax positions, a reminder that QIAGEN's Dutch holding structure and global intercompany financing involve judgment.³

Disclosed legal exposures are modest; the most notable is patent litigation with Labcorp as successor to ArcherDX.³ Related-party dealings are trivial, about 0.1% of sales.³ Pay is not extravagant by the standards of American peers: Bernard's 2025 compensation excluding long-term equity was about $2.4 million, and Roland Sackers, finance chief since 2004 and the one constant through Schatz, Bernard and Pratt, received about $1.3 million.³ The dissent at the annual meeting looks less like outrage over pay levels than a signal that a meaningful minority of holders wanted change at the top of a company whose growth had stalled.

Run the industry through Michael Porter's five forces and the picture sharpens. Buyer power is low per customer but high in aggregate: no single lab can squeeze QIAGEN, yet research funding cycles and government policy, from NIH budgets to immigration screening rules, move demand for whole customer groups at once, as 2026 showed. Supplier power is limited; QIAGEN discloses royalty obligations and some minimum purchase commitments, but no concentrated supplier dependency.³

The threat of new entrants in basic nucleic acid extraction is moderate: the chemistry is decades old and many companies make competing kits, but a new entrant must win validation in thousands of protocols, which takes years. Substitutes are the real long-run threat. Integrated platforms that combine extraction with testing inside a single cartridge, a trend QIAGEN itself joined with QIAstat-Dx, reduce the need for a standalone extraction step. Rivalry is intense with giants such as Thermo Fisher, Danaher and Roche, which can bundle sample preparation with instruments that QIAGEN failed to build.

Hamilton Helmer's framework asks which durable advantages a company actually holds. QIAGEN has a clear case for switching costs, grounded in validated workflows and a dispersed, repeat-buying customer base. It has a defensible case for a cornered resource in specific franchises: QuantiFERON's clinical evidence base and its automation partnerships, and the curated knowledge bases behind QIAGEN Digital Insights. Its brand is strong among scientists, which matters in research purchasing.

It does not have meaningful network effects, and its scale economies are real in manufacturing but smaller than those of the diversified giants it competes with. Counter-positioning, the power of a business model incumbents cannot copy without harming themselves, is absent; the picks-and-shovels model is easy for larger rivals to replicate inside their own broader catalogs. Process power, the advantage of a manufacturing or operating method that rivals cannot easily match, is plausible in its kit manufacturing quality but not demonstrated in the numbers.

The verdict: QIAGEN's moat is real but narrow. It protects the margins and the cash of an installed base; it does not, on the evidence of the last decade, produce growth on its own. That distinction is exactly the one an all-cash buyer at about 15 times forecast EBITDA is pricing.

Imagine, for a moment, the skeptical investor who has owned QIAGEN since the Thermo vote and is now deciding whether to tender. Their critique would not be about fraud or recklessness; the record shows neither. It would be about allocation. Since 2024 the company has sent more than $1.1 billion back to shareholders through buybacks and its new dividend, while spending a few hundred million on bolt-ons and letting research spending fall as a share of sales.¹¹³

That is a sensible policy for a mature cash generator. It is a strange one for a company that told the market, in June 2024, that it would compound sales at about 7% a year. The skeptic would ask which company management actually believed it was running, and would note that a private owner can run the cash-generator version with far more leverage and far less explaining.

The same skeptic would push on complexity. QIAGEN sells extraction kits to academic labs, tuberculosis tests to public health systems and immigration doctors, syndromic panels to hospitals, digital PCR to biopharma, genealogy searches to police and interpretation software to clinical geneticists. Each of those is a respectable business.

Together they share a brand, a manufacturing base and a sales force, but not a customer, a budget cycle or a growth driver. When one of them stumbles, as QuantiFERON did in 2026, there is no single story to tell investors, and the consolidated growth rate averages the winners down. A breakup, or a sharper portfolio, is the obvious option an activist would raise; it is also, quietly, one of the options a private owner gains.

For anyone following the company from here, three measures cut through the noise. The first is growth of the five pillars at constant currency, the company's own test of whether its focus strategy works: it ran at about 8% in 2025 and slowed to about 5% in the second quarter of 2026.¹¹²⁷

The second is QuantiFERON sales, the largest single franchise: about $503 million in 2025, guided flat in 2026 after the immigration shock, with second-quarter growth of 1%.¹⁰²⁷ The third is net leverage, which rose from 0.7 times to 1.1 times in the first half of 2026 and will be redefined entirely if EQT's debt lands on the balance sheet.²⁷ Those are the clues to watch, whoever ends up owning the company.

↑ Back to Top

X. Lessons

The first lesson begins with the meeting at Frankfurt airport that helped save the company. QIAGEN's history is a sequence of escapes, each driven by a decision about where to compete. The lesson for founders is that a great product in the wrong market is still a failing company. For QIAGEN, the market was always the decision; the chemistry was the easy part.

The second lesson lives in QIAGEN's failed attempts to build flagship instruments. A company that sells the shovels should not try to build the mine's biggest machine. QIAGEN's consumables advantage never transferred to flagship instruments, where scale and ecosystem decide the winner, and it paid for that lesson twice. The shovel-seller wins by being everywhere at step one, not by fighting for the center of the lab.

The third lesson is the failed Thermo Fisher tender: the shareholders were right about the moment and too hopeful about the trend. A pandemic can tell you what a business is worth in a crisis; it cannot tell you what it is worth when the crisis is over. A windfall is a price signal, not a growth rate.

The fourth lesson is the 2026 forecast reversal. QuantiFERON's fall in immigration testing showed that even a dispersed customer base can hide a concentrated policy exposure. When a single government rule decides whether thousands of people need your test, your largest customer is not a lab. It is a policy.

The fifth lesson is the arc from the millennium's genomics boom to today's private equity offer. QIAGEN proved that selling the picks and shovels is a wonderful business and a slow one. In a gold rush, the Levi Strauss model guarantees that you survive the bust. It does not guarantee that you share the boom.

↑ Back to Top

XI. Epilogue

Tonight QIAGEN is, in a precise legal sense, an independent company waiting to find out whether it will stay one. Its boards have recommended an offer that has not yet formally begun. The next step is a document: EQT's offer document must be cleared by BaFin, Germany's financial regulator, and only then does the acceptance period open, alongside a tender filing with the U.S. Securities and Exchange Commission.¹ Once it is published, the boards will issue their formal position statement, and shareholders will see, for the first time, the full conditions and the detail of the post-closing structure.¹

Then comes the vote that matters. At an extraordinary meeting held during the acceptance period, shareholders will decide whether to approve the measures that let EQT take full ownership. If at least 80% of votes cast approve them, the boards will implement them; if fewer do, the boards will have to decide whether a substantial majority of long-term holders supports the deal.¹ That is where the ghost of 2020 lives.

The largest disclosed holders today are mostly index and long-only managers, with BlackRock having reported about 13% of voting rights in September 2026 and Wellington, MFS and T. Rowe Price each having reported between 5% and 6% earlier in the year; management and directors own well under 1%.³⁷¹⁵ None of them has said publicly what it will do. Whether an event-driven fund repeats Davidson Kempner's play, buying shares to argue for more, is the first open question; the deal's 50% threshold and the boards' freedom to weigh such votes are designed to make that play much less effective.

There is also the question of what EQT is really buying, and the answer shapes the odds. A buyer paying about 15 times forecast cash earnings for a business that grows in low single digits is underwriting cash, cost and leverage, not a growth acceleration. If QIAGEN's pillars return to high single-digit growth under private ownership, EQT keeps the upside that public holders gave up.

If they do not, the debt will be serviced by the same consumables annuity that has carried the company through every downturn since the 1990s. Either way, the trade on offer to public holders is the certainty of €46.50 now against the uncertain value of a better QIAGEN later.

Two other clocks are running. Regulators must clear the deal, and QIAGEN has promised an interim dividend of up to $0.47 a share if approvals drag past ten months.¹ Pratt himself still needs a formal vote: he is to be proposed for appointment to the Managing Board at an extraordinary meeting planned for the fourth quarter of 2026.³² And the business keeps reporting.

The fourth quarter will be the first full quarter under Pratt, and the first glimpse of whether QuantiFERON's immigration reset has bottomed and whether the new sample preparation instruments are pulling consumables. Strong results would strengthen the hand of any holder who thinks €46.50 is too low; weak ones would make the offer look generous.

Set against the story's central questions, the outcomes sort cleanly. If the deal closes, QIAGEN's growth question passes to EQT, whose answer will be leverage, cost discipline and perhaps more acquisitions away from public view, and public shareholders will have accepted a price that values the moat's cash, not its hopes.

If the deal fails, QIAGEN returns to the public market with a new chief executive, a missed 2028 growth target, a stronger margin record and the uncomfortable knowledge that two buyers in six years have each been told the company is worth more than they would pay. Either way, the tension at the heart of QIAGEN remains exactly where it has been for forty years: an indispensable first step, and a stubborn uncertainty about what comes after it.

↑ Back to Top

XII. Outro

Peer Schatz built QIAGEN on the California gold-rush story, and Metin Colpan's 1986 plastic column gave it a product to match. Forty years later, its descendants still sit at the start of tuberculosis screens, forensic investigations, cancer research and wastewater surveillance on every continent.

QIAGEN tried to become a miner more than once, and the mine kept winning. Now a buyer from Stockholm is offering to take the shovel shop private, betting that a business this essential is worth more away from the market's impatience with its growth. Whether the shareholders agree is a question about price. Whether EQT is right is a question about the oldest idea in the company: that in every gold rush, somebody has to sell the shovels, and the trick is making sure the rush never ends.

References

1. QIAGEN and EQT Private Equity announce agreement on a recommended voluntary all-cash public takeover offer — QIAGEN, 2026-10-21 ↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩

2. QIAGEN Business Combination Agreement Announcement and Preliminary Q3 2026 Results — SEC, 2026-10-21 ↩↩

3. QIAGEN IFRS Annual Report 2025 — SEC, 2026 ↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩

4. Qiagen N.V. History — FundingUniverse (International Directory of Company Histories) ↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩

5. QIAGEN: A global leader in molecular diagnostics — BIO Deutschland ↩↩↩↩↩↩↩

6. QIAGEN Announces CEO Leadership Transition — BioSpace, 2019-10-07 ↩↩

7. QIAGEN and Digene announce definitive agreement to combine — SEC (Digene Form 8-K exhibit), 2007-06-03 ↩↩↩↩↩↩↩

8. QIAGEN announces 2028 strategy for solid profitable growth — QIAGEN, 2024-06-17 ↩↩↩↩↩↩↩↩

9. QIAGEN NV to acquire Cellestis Limited — Lab+Life Scientist, 2011-04-08 ↩

10. QIAGEN reports full results for Q1 2026 — SEC, 2026-05-06 ↩↩↩↩↩↩

11. QIAGEN Q4 and FY 2025 Results Call Script — QIAGEN, 2026-02-05 ↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩

12. QIAGEN Acquires Ingenuity Systems, Interpreter of Biological Information — Clinical Lab Products, 2013-04-30 ↩↩

13. Gilde Healthcare exits STAT-Dx to QIAGEN for $191M — Gilde Healthcare, 2018-05-02 ↩

14. Qiagen taps new CEO, restructures in "clearly a bad day" — MedTech Dive, 2019-10-08 ↩↩↩↩

15. QIAGEN Form 20-F 2024 — QIAGEN, 2025-03-28 ↩↩↩↩↩↩↩↩↩

16. Thermo Fisher nixes planned acquisition of Qiagen, fails to secure shareholder approval — MedTech Dive, 2020-08 ↩↩↩

17. Thermo Fisher Scientific to Acquire QIAGEN N.V. — SEC (Thermo Fisher Form 8-K exhibit), 2020-03-03 ↩↩↩

18. Shareholder challenges Thermo Fisher's $11.5B deal to buy Qiagen — MedTech Dive, 2020-07-13 ↩↩↩↩↩

19. Thermo Fisher ups Qiagen offer by 10% after investor backlash — MedTech Dive, 2020-07-16 ↩

20. Thermo Fisher: Results of Offer for QIAGEN, Lapse of Offer and Termination of Acquisition Agreement — SEC (Form 8-K exhibit), 2020-08-13 ↩↩

21. QIAGEN to continue successful growth strategy after voluntary public takeover offer falls short — BioSpace, 2020-08-13 ↩↩

22. QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million — QIAGEN, 2025-12-18 ↩↩

23. QIAGEN beats outlook for Q4 and full-year 2021 — SEC (Form 6-K), 2022-02-08 ↩↩

24. QIAGEN to discontinue NeuMoDx integrated PCR testing system — QIAGEN, 2024-06-06 ↩↩

25. QIAGEN U.S. GAAP Quarterly Report for the Period Ended June 30, 2024 — SEC, 2024 ↩

26. QIAGEN Strengthens Growing Portfolio of Applications for Its Digital PCR Platform QIAcuity — BioSpace, 2022-01-07 ↩↩

27. QIAGEN Q2 2026 Results — SEC, 2026-08-05 ↩↩↩↩↩↩↩↩↩↩↩

28. QIAGEN completes acquisition of Verogen — QIAGEN, 2023-01-09 ↩↩

29. QIAGEN to acquire Parse Biosciences — SEC (Form 6-K exhibit), 2025-11-04 ↩

30. QIAGEN announces CEO transition plan — QIAGEN, 2025-11-04 ↩

31. EQT to Acquire QIAGEN for $12.1B, Plans to Take Tools, Diagnostics Provider Private — GEN, 2026-10-22 ↩↩

32. Qiagen names new CEO — MedTech Dive, 2026-08-25 ↩↩↩↩↩

33. Qiagen agrees to private equity takeover — MedTech Dive, 2026-10-23 ↩

34. Thermo Fisher Valuation Snapshot — Stock Analysis ↩

35. Danaher Valuation Snapshot — Stock Analysis ↩

36. QIAGEN 2026 AGM Voting Results — SEC, 2026 ↩

37. QIAGEN Shareholder Structure — QIAGEN ↩